In addition, the target genes (CCND1, CCNE2, CDKN1A, VEGFA, FGF2, CHEK1, etc.)of miR-503-5p, which are potential therapeutic target for the treatment of PMO, are also enriched in some important pathways, such as “Cell cycle,” “Pathways in cancer,” “p53 signaling pathway,” “AMPK signaling,” “PI3K/AKT signaling,” “Wnt/beta-catenin Signaling,” et al. Another miRNA, Seeliger et al. (2014) and Bedene et al. (2016) showed that miR-148a-3p was a potential biomarker for the diagnosis and treatment of PMO. The gene discussed is TP53; the disease is cancer.